为解决梗阻性肥厚型心肌病（oHCM）患者长期治疗需求，Cytokinetics公司主导的FOREST-HCM开放标签扩展研究评估了心肌肌球蛋白抑制剂阿非卡姆坦（aficamten）的48周疗效。结果显示，药物显著降低左室流出道梯度（LVOT gradient）和心脏生物标志物水平，82%患者NYHA心功能 ...

本研究通过VALOR-HCM试验证实，Mavacamten可显著改善梗阻性肥厚型心肌病（oHCM）患者长期心脏重构，包括左心室流出道梯度（LVOT ...

Asymmetrical septal hypertrophy that causes a left-ventricular outflow tract (LVOT) gradient is a common feature of hypertrophic obstructive cardiomyopathy (HCOM). Septal myectomy is the standard ...

– Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM – – Four-week treatment with EDG-7500 demonstrated ...

People with symptomatic obstructive hypertrophic cardiomyopathy (HCM) gained functional capacity, and had left ventricular outflow tract (LVOT) gradients reduced, when treated with a cardiac myosin ...

Use of mavacamten, a novel cardiac myosin inhibitor, to treat people with symptomatic obstructive hypertrophic cardiomyopathy (HCM), a condition that results in excess thickening of the heart muscle, ...

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced new long-term follow-up results from the EXPLORER-LTE cohort of the MAVA-Long-Term Extension (LTE) study evaluating ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced results from the Phase 3 VALOR-HCM study, which showed the addition of mavacamten, an investigational, first-in-class ...

Please provide your email address to receive an email when new articles are posted on . Mavacamten presents dosing and drug-drug interaction challenges. A multidisciplinary approach featuring a ...